Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.

Nizar M. Tannir,Yu-Ning Wong,Christian Kollmannsberger,Marc S. Ernstoff,David J. Perry,Leonard Joseph Appleman,Edwin M. Posadas,Daniel Cho,Toni K. Choueiri,Andrew Coates,Neeraj Gupta,Rajendra S. Pradhan,J. Qian,Jihong Chen,Frank A. Scappaticci,J. L. Ricker,Dawn M. Carlson,M. Dror Michaelson

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.

2011

Nizar M. Tannir
Yu-Ning Wong
Christian Kollmannsberger
Marc S. Ernstoff
David J. Perry
Leonard Joseph Appleman
Edwin M. Posadas
Daniel Cho
Toni K. Choueiri
Andrew Coates
Neeraj Gupta
Rajendra S. Pradhan
J. Qian
Jihong Chen
Frank A. Scappaticci
J. L. Ricker
Dawn M. Carlson
M. Dror Michaelson

Purpose This study assessed the efficacy and safety of linifanib in patients with advanced renal cell carcinoma (RCC) who were previously treated with sunitinib.

Keywords:

Cell
Linifanib
Cancer
VEGF receptors
Renal cell carcinoma
Pathology
Medicine
Sunitinib
Carcinoma
cell cancer
in patient
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations